HAMP and anemia (phenotype): Likewise, hepcidin‐directed iron interventions would reach 68% of alpha thalassemia carriers (compared with 40% based on anemia‐screening), although the number of iron replete alpha thalassemia carriers receiving iron would be increased (from 13% to 28%).